Company intelligence / Profile preview

Astrego Diagnostics

Uppsala, Sweden

Ownership: Private
Employees: ~38
Development stage: Other

Overview

Astrego (now Sysmex Astrego) has developed and CE‑marked a rapid antimicrobial susceptibility test system based on microfluidic technology for urinary tract infections, enabling results in a short time frame compared with conventional AST; the system is being prepared and rolled out for primary care and central lab use in advanced markets[2][3][4][6].

Therapeutic areas: Infectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Molecular Diagnostics

Partnerships

Sysmex (strategic investor from 2019/2020 and commercial development partner for rapid AST for urinary tract infections)[3][4][6]

Beyond the preview

Go deeper on Astrego Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astrego Diagnostics.

Explore the full profile